Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa, Open-Label, Dose-Titration, Multicenter Study to Assess the Safety and Preliminary Efficacy of NI-0401 in Patients With Acute Cellular Renal Allograft Rejection

NCT00805909 is registered in ClinicalTrials.gov with Light Chain Bioscience - Novimmune SA as lead sponsor.

NCT NCT00805909
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00805909 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa, Open-Label, Dose-Titration, Multicenter Study to Assess the Safety and Preliminary Efficacy of NI-0401 in Patients With Acute Cellular Renal Allograft Rejection
Lead sponsor
Light Chain Bioscience - Novimmune SA
Phase
Phase 1/2
Overall status
Completed
Start date
August 31, 2007
Completion date
January 31, 2009
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute renal transplant rejection